US3634584A - Sustained action dosage form - Google Patents

Sustained action dosage form Download PDF

Info

Publication number
US3634584A
US3634584A US800827A US3634584DA US3634584A US 3634584 A US3634584 A US 3634584A US 800827 A US800827 A US 800827A US 3634584D A US3634584D A US 3634584DA US 3634584 A US3634584 A US 3634584A
Authority
US
United States
Prior art keywords
release
drug
peg
polyethylene glycol
vinyl polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US800827A
Inventor
John W Poole
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of US3634584A publication Critical patent/US3634584A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Definitions

  • the invention is directed to a sustained-release dosage form utilizing a carboxy vinyl polymer and polyethylene glycol complex as a means of controlling the rate of release of a drug, substantially independent of pH.
  • This invention relates to tableted therapeutic compositions with delayed release action including the ability to release a drug, or the active ingredient, gradually over relatively long periods of time, and to methods for preparing and using such compositions. More particularly, the invention relates to a sustained action dosage com position, containing a high molecular weight carboxy vinyl polymer and polyethylene glycol, and having a controlled rate of release of a contained drug, substantially independent of pH.
  • the slow release compositions of the prior art are pH dependent. That is, there is a delayed release of a drug in a medium having a pH from about pH 4 to about pH 11, but there is a rapid release of a drug in a medium of low pH where the polymeric material is not hydrated.
  • sustained action formulations of oxazepam utilizing the prior art compositions demonstrate a pH-dependent drug release.
  • an acidic solvent 0.1 N HCl
  • the polymer is not hydrated and consequently does not significantly retard the dissolution of the active component from the dosage unit.
  • a buffer solution pH 7.5
  • hydration of the polymer takes place with a resulting slowing of the release of the drug.
  • a sustained action system should be independent of pH so that the release of the drug would be independent of the foregoing factors.
  • FIG. 1 is a graph of the drug release characteristics of Patented Jan. 11, 1972 a typical pH-dependent drug release composition and of a composition of the present invention, both in an acidic medium and in an alkaline medium;
  • FIG. 2 is a graph of the phase solubility study of Carbopol 934 and polyethylene glycol having a molecular weight of about 4000;
  • FIG. 3 is a graph of the drug release characteristics of drug-containing compositions at various ratios of carboxy vinyl polymer and polyethylene glycol.
  • the rate of release of a drug from a therapeutic composition may be made substantially independent of pH where the composition includes a carboxy vinyl polymer and a polyethylene glycol.
  • the drug preferably is utilizable in powdered form.
  • the drug comprises about 1 to percent by weight, preferably 5 to 20 percent by weight, of the tablet composition.
  • the total of the carboxy vinyl polymer and polyethylene glycol preferably comprises about 10 to 60 percent by Weight, preferably about 20 to 50 percent by weight, of the composition.
  • the remainder of the composition may be a fast release drug, extenders, lubricants, flavoring agents, coloring agents and the like, as is well known in the art.
  • the carboxy vinyl polymer may be present in the amount of about 4 to 30 percent by weight, preferably about 10 to 30 percent. Advantageous results may be obtained when the carboxy vinyl polymer is present in the amount of about 15 to 25 percent by weight.
  • polyethylene glycol may be present in the amount of about 4 to 30 percent by weight, preferably about 10 to 30 percent by weight.
  • Advantageous results may be obtained where the polyethylene glycol is present in the amount of about 15 to 25 percent by weight.
  • the carboxy vinyl polymer is substantially insoluble in water and is the acid form of a polymer prepared as described in U.S. Pat. No. 2,798,053, granted July 2, 1957, selectively utilizing from about 0.75 to 2 percent by weight of polyalkenyl polyether, for example, polyallyl sucrose as the crosslinking material, the remainder being essentially acrylic acid or its equivalent and the polymerization being carried out in a hydrocarbon diluent with a free radical catalyst, for example, benzoyl peroxide.
  • the carboxy vinyl polymers employed in this invention are more specifically described in U.S. Pat. No. 2,909,462, of particular interest being the preparation produced in acid form.
  • a particularly effective embodiment of the high molecular weight carboxy vinyl polymer is a water-soluble polymer of acrylic acid crosslinked with 1% of a polyallyl ether of sucrose having an average of about 5.8 allyl groups for each molecule of sucrose (Carbopol 934) (formerly known as Good-rite K934).
  • the polyethylene glycol employed in the present invention may have a molecular weight from about 1,000 to 20,000, preferably 4,000 to 6,000.
  • the limiting factors are melting point at the lower molecular weights and solubility at the higher molecular weights, the determining factors being the dose form, storage conditions, and the like.
  • Advantageous results have been obtained with plyethylene glycol having a molecular weight of about 4,000, hereafter sometimes referred to as PEG 4000.
  • OXazepam is the generic name for 7-chloro-1,3-dihydro-3-hydroXy-5-phenyl-2H-1,4-benzodiazepine-Z-one.
  • the dosage and mode of administration of oxazepam and quinine are well known, see for instance, Physicians Desk Reference, 22nd edition, 1967, p. 124 etc. It is to be understood that the invention is applicable to other drugs as well.
  • Part 1 Tablets were prepared from the following control formula which does not contain polyethylene glycol.
  • the ingredients were weighed, screened, and blended, then densified by compacting in a tableting machine.
  • Dissolution tests on the tablets were performed using a low agitation procedure.
  • one tablet is placed in a two liter, round bottom flask containing 1750 milliliters of a solvent, and agitated. Agitation is accomplished by rotating a 7.5 centimeter Teflon paddle located 2.5 centimeters from the bottom of the flask at 50 revolutions per minute.
  • One group of Formula A tablets were placed in onetenth normal hydrochloric acid (0.1 N HCl). The pH of 0.1 N HCl is about 1.5. The amount of oxazepam in solution at various time intervals was recorded.
  • a second group of Formula A tablets was placed in 0.2 molar solution of disodium phosphate and monosodium phosphate buffered to a pH of 7.5. Samples were withdrawn at the times indicated by the dots in FIG. 1, either 1, 2, 3, 3 /2, 4, 5 or 6 hours. The samples were filtered and assayed for drug content. The results are shown in FIG. 1 where the percent of drug in solution is recorded.
  • Part 2 Tablets were prepared as in Part 1 in which the delayed release portion had the following formula which includes polyethylene glycol.
  • Curve A in FIG. 1 shows the amount of oxazepam from Formula A in solution in a pH 1.5 medium at various times after immersion.
  • Curve B in FIG. 1 shows the amount of oxazepam from Formula A in solution in a pH 7.5 medium at various times after immersion.
  • Curve C in FIG. 1 shows the amount of oxazepam from Formula B in solution in a pH 1.5 medium at various times after immersion.
  • Curve D in FIG. 1 shows the amount of oxazepam from Formula B in solution in a pH 7.5 medium at various times after immersion.
  • the oxazepam in tablets containing both Carbopol 934 and PEG 4000 was released at a rate substantially independent of pH.
  • the oxazepam in tabletswithout PEG 4000 was released more quickly in a pH 1.5 solution than in a pH 7.5 solution.
  • the oxazepam in tablets containing both Carbopol 934 and PEG 4000 was released at a rate that was substantially independent of pH. Also, there is a substantially lower release rate in an acidic medium such as gastric juices, so that the oxazepam will not be totally released in the stomach, but will continue to be released in the intestines and at a substantially uniform rate.
  • EXAMPLE 2 The following example illustrates the slow release of a readily water soluble compound.
  • the tricalcium phosphate acts as a diluent and the magnesium stearate as a lubricant.
  • the ingredients were weighed, screened, and blended, then densified by compacting in a tableting machine.
  • the tablets were crushed and screened as necessary to Obtain granules.
  • the granules were compacted in a tableting machine to form tablets for testing.
  • Dissolution tests on tablets of each formula were performed in a Stoll-Gershberg (U.S.P.) apparatus as follows. Two tablets were placed in a beaker in a basket without discs, in 500 milliliters of 0.1 N hydrochloric acid. The basket was oscillated and samples withdrawn, with filtration, at intervals of 15 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes and 180 minutes after tablet addition to the solution. Each withdrawn sample was diluted with aqueous solution and assayed spectrophotometrically for drug content. The results are shown in FIG. 3.
  • Formulations F and G with 'further progressively increasing concentrations of PEG showed a stepwise increase in the dissolution rate of the quinine hydrochloride from the minimum rate reached with Formula E. This is believed to be due to the presence of an excess of PEG in the presence of the Carbopol-PEG complex which functioned as a retarding mechanism. The excess PEG acted as a solubilizing agent to increase the dissolution of the quinine hydrochloride.
  • the rate of dissolution of an active ingredient may be readily con trolled by varying the PEG content and the ratio of Carbopol to PEG in the system.
  • an immediate-release portion of a drug may be included in one of several ways, such as in a separate layer of a double-layer tablet, or in the coating of a coated tablet.
  • EXAMPLE 3 The following example illustrates the preparation of a two-layered tablet embodiment of a composition of this invention.
  • Layer 1.S'ustained action portion Oxazepam 30 Carbopol 934 75 Avicel (monocrystalline cellulose) 150 Carbowax 4000 .(PEG 4000) 75 Lactose, monohydrate, USP 162 Magnesium stearate USP 8 Total 500 Layer 2.Fast release portion Oxazepam l5 Methylcellulose (400 cps.) 30 Amberlite IRPEA 3 FDA Yellow No. 5 lake 1.9 Magnesium stearate USP 1.5 Lactose, monohydrate, USP 138.6
  • the total tablet weight was 690 mg.
  • Preparation of layer 1 All of the ingredients were mixed and screened then slugged on a tableting machine. The slugs were comminuted to produce granules of predetermined size. The granules were the compressed as a first layer in a doublelayer, tableting machine.
  • the dissolution rate of the drug contained in layer 1 is substantially similar to that shown in curve D of FIG. 1, when tested by the procedure of Example 1.
  • EXAMPLE 4 The following example illustrates the preparation of a tablet by a wet granulation method.
  • the sustained release layer of the tablet was prepared with:
  • Magnesium stearate USP 8 Total weight 500 All of the solid ingredients except magnesium stearate were wet granulated by mixing with ethyl ether, placed in trays and dried in an atmospheric oven at degrees F. The dried mixture was passed through a number 12 (U.S. Standard sieve series) wire screen, and magnesium stearate was added through a number 30 screen. The ingredients were mixed thoroughly and pressed on a tablet press.
  • the fast release layer had the same formula as the fast release layer of Example 3 and was prepared by dry granulation as in Example 3. A two-layer tablet was formed as described in Example 3.
  • the dissolution of the active ingredient from the sustained release layer portion was shown to be substantially the same in a pH 7.4 phosphate buffer as that shown in curve D of FIG. 1.
  • Tablets may also be prepared following the above procedure but substituting absolute ethyl alcohol for ethyl ether in the granulating solution or by substituting PEG 6000, PEG 10,000, or PEG 20,000 for the PEG 4.000.
  • Mephentermine sulfate powder 150 Carpobol 934 150 PEG 6000 150 Powdered sucrose 40 Talc Total 500 EXAMPLE 6 Sustained release tablets are prepared by the procedure of Example 1, but substituting the following formula per tablet:
  • tablets comprises intimately mixing a powdered drug with a carboxy vinyl polymer of acrylic acid copolymerized with about 0.75 to 2 percent of polyalkenyl polyether, and polyethylene glycol having a molecular weight of about 1,000 to 20,000 in which the drug comprises about 1 to percent by weight of the mixture, and the carboxy vinyl polymer together with the polyethylene glycol comprises about 10 to 60 percent by weight of the composition, the latter being present in a ratio of about 1:05 to 1:3.8 to each other, and then compressing the intimately mixed ingredients to form tablets for oral medication.
  • FIG. 2 is a graph of a phase solubility study of Carbopol 934 and PEG 4000.
  • known amounts of various concentrations by weight of PEG 4000 were added to known amounts of an aqueous solution of 0.5 percent by weight of Carbopol 934.
  • the amount of PEG 4000 remaining in solution was determined and subtracted from the total PEG 4000 added to determine the amount of PEG 4000 in the complex.
  • the slope of the curve of FIG. 2 indicates that the interaction is about 1:1.5 on a weight basis of the two polymers Carbopol 934 and PEG 4000.
  • the ratio may vary through a range of 1:05 to 123.0.
  • a tablet consisting essentially of (A) A powdered, orally effective drug in an amount sufficient to give a pharmacologic response upon ingestion and absorption, said drug being intimately mixed with (B) A substantially acid carboxy vinyl polymer of acrylic acid cross-linked with about 0.75 to about 2 percent by weight of a polyalkenyl polyether, and
  • a tablet composition as defined in claim 1 in the form of a double layer or coated tablet which further comprises a ready release portion of the same drug or a different drug included in a separate layer of the double layer tablet, or in the coating of a coated tablet.
  • Carboxy vinyl polymer 15-25 Polyethylene glycol 15-25 Diluents, lubricants, flavoring and the like 5-65 References Cited UNITED STATES PATENTS 2,987,445 6/1961 Levesque 42419 3,039,933 6/1962 Goldman 42419 3,065,143 11/1962 Christenson et al. 42419 3,074,852 1/1963 Mayron 42419 3,096,248 7/1963 Rudski 42419 X 3,158,538 11/1964 Lee 42419 X 3,308,217 3/1967 Lowy et al.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

THE INVENTION IS DIRECTED TO A SUSTAINED-RELEASE DOSAGE FORM UTILIZING A CARBOXY VINYL POLYMER AND POLYETHYLENE GLYCOL COMPLEX AS A MEANS OF CONTROLLING THE RATE OF RELEASE OF A DRUG, SUBSTANTIALLY INDEPENDENT OF PH.

Description

Jan. 11, 1972 J. w. POOLE 3,634,584
SUSTAINED ACTION DOSAGE FORM Filed Feb. 13, 1969 3 Sheets-Sheet 1 PER CENT IN SOLUTION 0 I l l l l l 2 3 4 5 TIME(HOURS) Jan. 11, 1972 J, w. PooLE SUSTAINED ACTION DOSAGE FORM 3 Sheets-Sheet 2 Filed Feb. 13, 1969 owoo ooov owl Pzwu mum 2! we we 8 m mo v 0 no we (HWUO :l XTIdWOI) 'lVlOl Jan. 11, 1972 J. W. POOLE SUSTAINED ACTION DOSAGE FORM 3 Sheets-Sheet 8 Filed Feb. 13. 1969 (HOURS) TIME FIG.3
United States Patent U.S. Cl. 424-21 8 Claims ABSTRACT OF THE DISCLOSURE The invention is directed to a sustained-release dosage form utilizing a carboxy vinyl polymer and polyethylene glycol complex as a means of controlling the rate of release of a drug, substantially independent of pH.
This application is a continuation-in-part of application Ser. No. 730,742 filed May 21, 1968, now abandoned.
This invention relates to tableted therapeutic compositions with delayed release action including the ability to release a drug, or the active ingredient, gradually over relatively long periods of time, and to methods for preparing and using such compositions. More particularly, the invention relates to a sustained action dosage com position, containing a high molecular weight carboxy vinyl polymer and polyethylene glycol, and having a controlled rate of release of a contained drug, substantially independent of pH.
Various processes and compositions have been proposed for delaying or prolonging the release of medicaments in oral form. One such composition is disclosed in U.S. Pat. 3,074,852 in which a solid medicinal component is combined with a carboxy vinyl polymer, such as Carbopol 934.
The slow release compositions of the prior art are pH dependent. That is, there is a delayed release of a drug in a medium having a pH from about pH 4 to about pH 11, but there is a rapid release of a drug in a medium of low pH where the polymeric material is not hydrated.
For example, sustained action formulations of oxazepam utilizing the prior art compositions demonstrate a pH- dependent drug release. In an acidic solvent (0.1 N HCl), representing gastric fluid, the polymer is not hydrated and consequently does not significantly retard the dissolution of the active component from the dosage unit. However, in a buffer solution (pH 7.5) representing the intestinal fluid, hydration of the polymer takes place with a resulting slowing of the release of the drug.
Because the acid content of the stomach varies considerably and the time interval during which a dosage composition remains in the stomach also varies, ideally, a sustained action system should be independent of pH so that the release of the drug would be independent of the foregoing factors.
It is an object of the present invention to provide a medicinal composition having delayed release characteristics which is substantially independent of pH.
It is another object of the present invention to provide a pharmaceutical composition which is capable of releasing drug immediately and then uniformly over long periods of time.
It is another object of this invention to provide a pharmaceutical composition in which the rate of release of drugs of different solubilities may be controlled.
Other objects and features of the invention will be apparent to those skilled in the art from reading the following description, taken in conjunction with the drawings in which:
FIG. 1 is a graph of the drug release characteristics of Patented Jan. 11, 1972 a typical pH-dependent drug release composition and of a composition of the present invention, both in an acidic medium and in an alkaline medium;
FIG. 2 is a graph of the phase solubility study of Carbopol 934 and polyethylene glycol having a molecular weight of about 4000; and
FIG. 3 is a graph of the drug release characteristics of drug-containing compositions at various ratios of carboxy vinyl polymer and polyethylene glycol.
It has been found that the rate of release of a drug from a therapeutic composition may be made substantially independent of pH where the composition includes a carboxy vinyl polymer and a polyethylene glycol. The drug preferably is utilizable in powdered form. The drug comprises about 1 to percent by weight, preferably 5 to 20 percent by weight, of the tablet composition. The total of the carboxy vinyl polymer and polyethylene glycol preferably comprises about 10 to 60 percent by Weight, preferably about 20 to 50 percent by weight, of the composition. The remainder of the composition may be a fast release drug, extenders, lubricants, flavoring agents, coloring agents and the like, as is well known in the art.
The carboxy vinyl polymer may be present in the amount of about 4 to 30 percent by weight, preferably about 10 to 30 percent. Advantageous results may be obtained when the carboxy vinyl polymer is present in the amount of about 15 to 25 percent by weight.
Similarly the polyethylene glycol may be present in the amount of about 4 to 30 percent by weight, preferably about 10 to 30 percent by weight. Advantageous results may be obtained where the polyethylene glycol is present in the amount of about 15 to 25 percent by weight.
It was discovered that the incorporation of a polyethylene glycol and a carboxy vinyl polymer in a therapeu tic formulation resulted in a product demonstrating a significant decrease in the rate of drug release in an acidic medium, with substantially no effect on the rate of release in a pH 7.5 medium. Without wishing to be bound by a theory of operation, the probable mechanism by which this delayed release occurs in the acidic medium is through the formation of a molecular complex between the polyethylene glycol and the carboxy vinyl polymer. The complex, however, is apparently not stable in a basic medium, and in the latter environment the normal hydration of the carboxy vinyl polymer acts as a delayingmechanism. By varying the ratio of complexable to free polymeric substances in the dosage form, the release of drugs of varying solubilities may be controlled.
The carboxy vinyl polymer is substantially insoluble in water and is the acid form of a polymer prepared as described in U.S. Pat. No. 2,798,053, granted July 2, 1957, selectively utilizing from about 0.75 to 2 percent by weight of polyalkenyl polyether, for example, polyallyl sucrose as the crosslinking material, the remainder being essentially acrylic acid or its equivalent and the polymerization being carried out in a hydrocarbon diluent with a free radical catalyst, for example, benzoyl peroxide. The carboxy vinyl polymers employed in this invention are more specifically described in U.S. Pat. No. 2,909,462, of particular interest being the preparation produced in acid form. A particularly effective embodiment of the high molecular weight carboxy vinyl polymer is a water-soluble polymer of acrylic acid crosslinked with 1% of a polyallyl ether of sucrose having an average of about 5.8 allyl groups for each molecule of sucrose (Carbopol 934) (formerly known as Good-rite K934).
The polyethylene glycol employed in the present invention may have a molecular weight from about 1,000 to 20,000, preferably 4,000 to 6,000. The limiting factors are melting point at the lower molecular weights and solubility at the higher molecular weights, the determining factors being the dose form, storage conditions, and the like. Advantageous results have been obtained with plyethylene glycol having a molecular weight of about 4,000, hereafter sometimes referred to as PEG 4000.
The use of the invention to control the release of drugs from tablets containing a carboxy vinyl polymer-polyethylene glycol mixture has been demonstrated with a substantially insoluble drug, oxazepam, and With quinine salt, a readily soluble drug. OXazepam is the generic name for 7-chloro-1,3-dihydro-3-hydroXy-5-phenyl-2H-1,4-benzodiazepine-Z-one. The dosage and mode of administration of oxazepam and quinine are well known, see for instance, Physicians Desk Reference, 22nd edition, 1967, p. 124 etc. It is to be understood that the invention is applicable to other drugs as well.
EXAMPLE I The following example illustrates the effect on the dissolution rate of a relatively insoluble compound.
Part 1 Tablets were prepared from the following control formula which does not contain polyethylene glycol.
The ingredients were weighed, screened, and blended, then densified by compacting in a tableting machine.
Dissolution tests on the tablets were performed using a low agitation procedure. In such a procedure one tablet is placed in a two liter, round bottom flask containing 1750 milliliters of a solvent, and agitated. Agitation is accomplished by rotating a 7.5 centimeter Teflon paddle located 2.5 centimeters from the bottom of the flask at 50 revolutions per minute.
One group of Formula A tablets were placed in onetenth normal hydrochloric acid (0.1 N HCl). The pH of 0.1 N HCl is about 1.5. The amount of oxazepam in solution at various time intervals was recorded. A second group of Formula A tablets was placed in 0.2 molar solution of disodium phosphate and monosodium phosphate buffered to a pH of 7.5. Samples were withdrawn at the times indicated by the dots in FIG. 1, either 1, 2, 3, 3 /2, 4, 5 or 6 hours. The samples were filtered and assayed for drug content. The results are shown in FIG. 1 where the percent of drug in solution is recorded.
Part 2 Tablets were prepared as in Part 1 in which the delayed release portion had the following formula which includes polyethylene glycol.
FORMULA B Milli- Weight Ingredient grams percent Oxazepam 30 7. 8 Carbopol 934 (2.5% Carbosil) 93 24. 2 PE G 4000 75 19. 5 Lactose 180 46. 7 Magnesium stearate 7 1. 8
Curve A in FIG. 1 shows the amount of oxazepam from Formula A in solution in a pH 1.5 medium at various times after immersion.
Curve B in FIG. 1 shows the amount of oxazepam from Formula A in solution in a pH 7.5 medium at various times after immersion.
Curve C in FIG. 1 shows the amount of oxazepam from Formula B in solution in a pH 1.5 medium at various times after immersion.
Curve D in FIG. 1 shows the amount of oxazepam from Formula B in solution in a pH 7.5 medium at various times after immersion.
As may be seen from a comparison of curves A and B with curves C and D, the oxazepam in tablets containing both Carbopol 934 and PEG 4000 was released at a rate substantially independent of pH. The oxazepam in tabletswithout PEG 4000 was released more quickly in a pH 1.5 solution than in a pH 7.5 solution. The oxazepam in tablets containing both Carbopol 934 and PEG 4000 was released at a rate that was substantially independent of pH. Also, there is a substantially lower release rate in an acidic medium such as gastric juices, so that the oxazepam will not be totally released in the stomach, but will continue to be released in the intestines and at a substantially uniform rate.
Other tablets having sustained release characteristics may be prepared by the foregoing procedure but substituting other active ingredients for oxazepam. Such active ingredients include:
amphetamine sulfate acetyl salicylic acid aminophylline antazoline hydrochloride alkaloids of belladonna ampicillin ascorbic acid atropine sulfate aureomycin bethanecholchloride caffeine codeine sulfate colchicine cortisone dextroamphetamine sulfate digitoxin dihydrostreptomycin dienestrol diethyl carbamazine citrate diethylpropion doxylamine succinate d-methorphan hydrobromide erythrityltetranitrate ephedrine sulfate erogonovine maleate ethisterone hexocyclium methylsulfate isoniazid morphine sulfate meprobamate mercurophylline methyltestosterone methamphetamine hydrochloride neostigmine bromide nicotinic acid nicotinamide N-acetyl-p-aminophenol pentobarbital pyrilamine maleate pilocarpine hydrochloride progestrone prednisone propylthiouracil piperazine tartrate phenobarbital sodium promazine hydrochloride potassium phenoxymethyl penicillin pheniramine maleate piperazine tartrate quinidine sulfate quinine sulfate reserpine sodium penicillin sodium salicylate sulfadi azine sulfanilamide tolbutamide tolazoline hydrochloride and their pharmaceutically active acid-addition salts.
EXAMPLE 2 The following example illustrates the slow release of a readily water soluble compound.
Twenty tablets were prepared according to each of the following formulas where amounts are stated in grams.
The tricalcium phosphate acts as a diluent and the magnesium stearate as a lubricant.
The ingredients were weighed, screened, and blended, then densified by compacting in a tableting machine. The tablets were crushed and screened as necessary to Obtain granules. The granules were compacted in a tableting machine to form tablets for testing.
Dissolution tests on tablets of each formula were performed in a Stoll-Gershberg (U.S.P.) apparatus as follows. Two tablets were placed in a beaker in a basket without discs, in 500 milliliters of 0.1 N hydrochloric acid. The basket was oscillated and samples withdrawn, with filtration, at intervals of 15 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes and 180 minutes after tablet addition to the solution. Each withdrawn sample was diluted with aqueous solution and assayed spectrophotometrically for drug content. The results are shown in FIG. 3.
The results show that with no polyethylene glycol present there was substantially no retardation of the dissolution of the quinine hydrochloride in the pH 1.5 medium. Formulations B, C, D and E with progressively increasing quantities of PEG showed a stepwise decrease in the dissolution of the quinine hydrochloride reaching the slowest rate of dissolution in sample B. In sample B the PEG content was 15% by weight and the ratio of Carbopol 934 to PEG was 1: 1.5.
Formulations F and G with 'further progressively increasing concentrations of PEG showed a stepwise increase in the dissolution rate of the quinine hydrochloride from the minimum rate reached with Formula E. This is believed to be due to the presence of an excess of PEG in the presence of the Carbopol-PEG complex which functioned as a retarding mechanism. The excess PEG acted as a solubilizing agent to increase the dissolution of the quinine hydrochloride.
It may be inferred from the foregoing data that the rate of dissolution of an active ingredient may be readily con trolled by varying the PEG content and the ratio of Carbopol to PEG in the system.
From the foregoing data it is apparent that the use of varying relative amounts of the carboxy vinyl polymer and polyethylene glycol will permit the formulation of a sustained action system giving a desired release rate of a drug, substantially independent of pH.
If desirable, an immediate-release portion of a drug may be included in one of several ways, such as in a separate layer of a double-layer tablet, or in the coating of a coated tablet.
EXAMPLE 3 The following example illustrates the preparation of a two-layered tablet embodiment of a composition of this invention.
Layer 1.S'ustained action portion Oxazepam 30 Carbopol 934 75 Avicel (monocrystalline cellulose) 150 Carbowax 4000 .(PEG 4000) 75 Lactose, monohydrate, USP 162 Magnesium stearate USP 8 Total 500 Layer 2.Fast release portion Oxazepam l5 Methylcellulose (400 cps.) 30 Amberlite IRPEA 3 FDA Yellow No. 5 lake 1.9 Magnesium stearate USP 1.5 Lactose, monohydrate, USP 138.6
Total 190.0
The total tablet weight was 690 mg.
Preparation of layer 1 All of the ingredients were mixed and screened then slugged on a tableting machine. The slugs were comminuted to produce granules of predetermined size. The granules were the compressed as a first layer in a doublelayer, tableting machine.
Preparation of layer 2 All of the ingredients were mixed and screened then slugged on a tableting machine. The slugs were reduced in particle size and the resulting granules were recompressed as the second layer of the above tablets in a double-layer, tableting machine.
The dissolution rate of the drug contained in layer 1 is substantially similar to that shown in curve D of FIG. 1, when tested by the procedure of Example 1.
EXAMPLE 4 The following example illustrates the preparation of a tablet by a wet granulation method.
The sustained release layer of the tablet was prepared with:
Oxazepam 30 PEG 4000 7S Carbopol 934 75 Avicel 150 Lactose hydrous USP powder 162 Magnesium stearate USP 8 Total weight 500 All of the solid ingredients except magnesium stearate were wet granulated by mixing with ethyl ether, placed in trays and dried in an atmospheric oven at degrees F. The dried mixture was passed through a number 12 (U.S. Standard sieve series) wire screen, and magnesium stearate was added through a number 30 screen. The ingredients were mixed thoroughly and pressed on a tablet press.
The fast release layer had the same formula as the fast release layer of Example 3 and was prepared by dry granulation as in Example 3. A two-layer tablet was formed as described in Example 3.
The dissolution of the active ingredient from the sustained release layer portion was shown to be substantially the same in a pH 7.4 phosphate buffer as that shown in curve D of FIG. 1.
Tablets may also be prepared following the above procedure but substituting absolute ethyl alcohol for ethyl ether in the granulating solution or by substituting PEG 6000, PEG 10,000, or PEG 20,000 for the PEG 4.000.
EXAMPLE Sustained release tablets are prepared by the procedure of Example 4, but substituting the following formula per tablet:
Mephentermine sulfate powder 150 Carpobol 934 150 PEG 6000 150 Powdered sucrose 40 Talc Total 500 EXAMPLE 6 Sustained release tablets are prepared by the procedure of Example 1, but substituting the following formula per tablet:
Promazine hydrochloride powder Carbopol 934 125 PEG 20,000 125 Calcium stearate USP 11 Kaolin 214 Total 500 EXAMPLE 7 Sustained release tablets are prepared by the procedure of Example 1, but substituting the following formula per tablet:
EXAMPLE 8 Sustained release tablets are prepared by the procedure of Example 1, but substituting the following formula per tablet:
Crystalline acetylsalicylic acid (40 mesh USP) 300 Carbopol 934 75 PEG 20,000 75 White mineral oil 10 Dry starch 40 Total 500 EXAMPLE 9 Sustained release tablets are prepared by the procedure of Example 1, but substituting the following formula per tablet:
Mg. Potassium phenoxymethyl penicillin 250 Carbopol 934 75 PEG 4000 75 Sodium benzoate 10 Lactose (milk sugar) 90 Total To A process for making the sustained action pharmaceutical. tablets comprises intimately mixing a powdered drug with a carboxy vinyl polymer of acrylic acid copolymerized with about 0.75 to 2 percent of polyalkenyl polyether, and polyethylene glycol having a molecular weight of about 1,000 to 20,000 in which the drug comprises about 1 to percent by weight of the mixture, and the carboxy vinyl polymer together with the polyethylene glycol comprises about 10 to 60 percent by weight of the composition, the latter being present in a ratio of about 1:05 to 1:3.8 to each other, and then compressing the intimately mixed ingredients to form tablets for oral medication.
The existence of a carboxy vinyl polymer-polyethylene glycol complex may be demonstrated as follows. A solution of polyethylene glycol is added to a solution of carboxy vinyl polymer at various pHs. A precipitate forms below about pH 4. No precipitate forms when the pH is about 4 or higher. The results indicate the formation of an insoluble complex below about pH 4, but not above about pH 4.
FIG. 2 is a graph of a phase solubility study of Carbopol 934 and PEG 4000. In carrying out the study known amounts of various concentrations by weight of PEG 4000 were added to known amounts of an aqueous solution of 0.5 percent by weight of Carbopol 934. The amount of PEG 4000 remaining in solution was determined and subtracted from the total PEG 4000 added to determine the amount of PEG 4000 in the complex. The slope of the curve of FIG. 2 indicates that the interaction is about 1:1.5 on a weight basis of the two polymers Carbopol 934 and PEG 4000. The ratio may vary through a range of 1:05 to 123.0.
The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed.
What is claimed is:
1. A tablet consisting essentially of (A) A powdered, orally effective drug in an amount sufficient to give a pharmacologic response upon ingestion and absorption, said drug being intimately mixed with (B) A substantially acid carboxy vinyl polymer of acrylic acid cross-linked with about 0.75 to about 2 percent by weight of a polyalkenyl polyether, and
(C) Polyethylene glycol having a molecular weight of about 1,000 to 20,000 in which said drug comprises about 1 to 90 percent by weight of the mixture, and said carboxy vinyl polymer together with said polyethylene glycol comprise about 10 to 60 percent by weight of the compositiomthe latter being present in a ratio of about 1:0.5 to 123.0 to each other, said admixture then having been subjected to suflicient pressure to form a medicinal tablet; the rate of dissolution of (A) being readily controlled and substantially independent of pH by varying the content of (C) and the ratio of (B) to (C), the release of ,(A) of varying solubilities being further controllable by varying the ratio of complexable to free polymeric substance of (B) and (C), said tablet, on oral administration adapted to provide an insoluble molecular complex, unstable in basic media occurring between (C) and (B), in acidic media below about pH 4, said molecular complex functioning as the retarding mechanism.
2. A tablet composition as defined in claim 1 in the form of a double layer or coated tablet which further comprises a ready release portion of the same drug or a different drug included in a separate layer of the double layer tablet, or in the coating of a coated tablet.
3. A tablet composition as defined in claim 1 in which said carboxy vinyl polymer is present in the amount of 10 to 30 percent by weight and said polyethylene glycol is present in the amount of 5 to 30 percent by Weight.
Milligrams Oxazepam 15-60 Carboxy vinyl polymer 20-150 Polyethylene glycol 20-150 Extenders, lubricants, flavoring and the like 5-450 7. A tablet composition as defined in claim 1 in which the components are as follows:
Milligrams Quinine salt 15-60 Carboxy vinyl polymer 20-150 Polyethylene glycol 20-150 Extenders, lubricants, flavoring and the like 5-450 8. A tablet composition as defined in claim 1 in which the components are as follows:
Percent by wt. 6 (1 aminocyclohexanecarboxamido)-3,3-dimethyl 7 x0 4 thio-l-azabicyclo [3.2.0]
heptane-Z-carboxylic acid -20 \Percent by wt. Carboxy vinyl polymer 15-25 Polyethylene glycol 15-25 Diluents, lubricants, flavoring and the like 5-65 References Cited UNITED STATES PATENTS 2,987,445 6/1961 Levesque 42419 3,039,933 6/1962 Goldman 42419 3,065,143 11/1962 Christenson et al. 42419 3,074,852 1/1963 Mayron 42419 3,096,248 7/1963 Rudski 42419 X 3,158,538 11/1964 Lee 42419 X 3,308,217 3/1967 Lowy et al. 42419 X 3,330,729 7/1967 Johnson 42419 3,346,449 10/1967 Magid 424-19 X 3,379,554 4/1968 Brindamour 42419 X 3,458,622 7/1969 Hill 42419 3,459,850 8/1969 Riva 42419 X SHEP K. ROSE, Primary Examiner US. Cl. X.R. 42419, 22
US800827A 1969-02-13 1969-02-13 Sustained action dosage form Expired - Lifetime US3634584A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80082769A 1969-02-13 1969-02-13

Publications (1)

Publication Number Publication Date
US3634584A true US3634584A (en) 1972-01-11

Family

ID=25179474

Family Applications (1)

Application Number Title Priority Date Filing Date
US800827A Expired - Lifetime US3634584A (en) 1969-02-13 1969-02-13 Sustained action dosage form

Country Status (1)

Country Link
US (1) US3634584A (en)

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3938515A (en) * 1971-12-20 1976-02-17 Alza Corporation Novel drug permeable wall
US4248857A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4343789A (en) * 1979-07-05 1982-08-10 Yamanouchi Pharmaceutical Co., Ltd. Sustained release pharmaceutical composition of solid medical material
EP0108218A3 (en) * 1982-10-08 1984-11-28 Verex Laboratories, Inc. Constant release rate solid oral dosage formulation of pharmaceutical compounds having a high degree of water solubility
WO1986000802A1 (en) * 1984-07-23 1986-02-13 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4647599A (en) * 1983-11-11 1987-03-03 Egyt Gyogyszervegyeszeti Cyar Sustained release pharmaceutical tablets and process for the preparation thereof
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US4708874A (en) * 1985-03-13 1987-11-24 Rijksuniversiteit Groningen Devices for the controlled release of active substances, as well as process for the preparation thereof
US4720387A (en) * 1983-06-22 1988-01-19 Shionogi & Co., Ltd. Sustained-release preparation of pinacidil
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4772473A (en) * 1986-06-16 1988-09-20 Norwich Eaton Pharmaceuticals, Inc. Nitrofurantoin dosage form
US4798725A (en) * 1986-06-16 1989-01-17 Norwich Eaton Pharmaceuticals, Inc. Sustained release capsule
US4839177A (en) * 1985-12-20 1989-06-13 Jagotec Ag System for the controlled-rate release of active substances
EP0309404A3 (en) * 1987-09-25 1990-03-14 Battelle Memorial Institute Bioadhesive copolymer useful as a carrier in the administration of medicines by direct contact
US5051262A (en) * 1979-12-07 1991-09-24 Elan Corp., P.L.C. Processes for the preparation of delayed action and programmed release pharmaceutical forms and medicaments obtained thereby
US5213808A (en) * 1989-09-22 1993-05-25 Buhk Meditec A/A Controlled release article with pulsatile release
US5302398A (en) * 1991-04-12 1994-04-12 Alfa Wassermann S.P.A. Gastroresistant pharmaceutical formulations for oral administration containing salts of bile acids
GB2281204A (en) * 1993-07-27 1995-03-01 Euro Celtique Sa Sustained release morphine compositions
GB2284760A (en) * 1993-11-23 1995-06-21 Euro Celtique Sa Sustained release morphine compositions
US5618560A (en) * 1988-03-24 1997-04-08 Bm Research A/S Controlled release erodible composition
US5651985A (en) * 1994-02-28 1997-07-29 Bayer Aktiengesellschaft Expandable pharmaceutical forms
US5672360A (en) * 1993-11-23 1997-09-30 Purdue Pharma, L.P. Method of treating pain by administering 24 hour oral opioid formulations
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US6080428A (en) * 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6103261A (en) * 1993-07-01 2000-08-15 Purdue Pharma Lp Opioid formulations having extended controlled release
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
JP2003512402A (en) * 1999-10-27 2003-04-02 アネスタ・コーポレーション Oral transmucosal drug dosage form using solid solution
US20030215508A1 (en) * 2000-04-28 2003-11-20 Davis Robert D. Sustained release of guaifenesin combination drugs
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US20040018233A1 (en) * 2000-04-28 2004-01-29 Davis Robert D. Sustained release of guaifenesin
US20040022851A1 (en) * 2000-04-28 2004-02-05 Davis Robert D. Sustained release of guaifenesin combination drugs
US20040047907A1 (en) * 2000-10-30 2004-03-11 Benjamin Oshlack Controlled release hydrocodone formulations
US20040096500A1 (en) * 1991-11-27 2004-05-20 Benjamin Oshlack Controlled release oxycodone compositions
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US20040170680A1 (en) * 2001-05-02 2004-09-02 Benjamin Oshlack Once-a-day oxycodone formulations
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US20040222166A1 (en) * 2003-05-05 2004-11-11 J.F. Daley International, Ltd. Solid algicide, preparation and usage in recirculating water
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US20040266807A1 (en) * 1999-10-29 2004-12-30 Euro-Celtique, S.A. Controlled release hydrocodone formulations
US20050025832A1 (en) * 1996-11-12 2005-02-03 Alza Corporation Methods and devices for providing prolonged drug therapy
US20050276852A1 (en) * 2000-04-28 2005-12-15 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US20060099263A1 (en) * 1993-05-27 2006-05-11 Edgren David E Antidepressant dosage form
US20060263427A1 (en) * 2005-05-03 2006-11-23 Roberts Richard H Quinine formulations
US20070190145A1 (en) * 2006-01-27 2007-08-16 Eurand, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
US20070196491A1 (en) * 2006-01-27 2007-08-23 Eurand, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
US20070232667A1 (en) * 1993-09-20 2007-10-04 Eugenio Cefali Methods for Treating Hyperlipidemia With Intermediate Release Nicotinic Acid Compositions Having Unique Biopharmaceutical Characteristics
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US20080020032A1 (en) * 2006-07-21 2008-01-24 Michael Crowley Hydrophobic abuse deterrent delivery system for hydromorphone
US20080045573A1 (en) * 1993-09-20 2008-02-21 Bova David J Methods and Sustained Release Nicotinic Acid Compositions for Treating Hyperlipidemia
US20080055036A1 (en) * 2006-08-29 2008-03-06 International Business Machines Corporation Electrical component tuned by conductive layer deletion
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US20090232885A1 (en) * 2008-03-12 2009-09-17 Gopi Venkatesh Drug Delivery Systems Comprising Weakly Basic Drugs and Organic Acids
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US20110150992A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and method of use thereof
US20120269866A1 (en) * 2007-07-06 2012-10-25 Shaukat Ali Gastroretentive Composition On The Basis Of A Water-Soluble Reaction Product From A Vinyl Group-Containing Precursor
US8936810B2 (en) 1998-06-03 2015-01-20 Alza Corporation Methods and apparatus for determining formulation orientation of multi-layered pharmaceutical dosage forms
WO2016123482A3 (en) * 2015-01-30 2016-10-06 Mylan, Inc. Sustained-release oral dosage forms for low aqueous solubility compounds
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
US12370189B2 (en) 2014-10-21 2025-07-29 Rb Health (Us) Llc Pharmaceutical formulation

Cited By (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3938515A (en) * 1971-12-20 1976-02-17 Alza Corporation Novel drug permeable wall
US4343789A (en) * 1979-07-05 1982-08-10 Yamanouchi Pharmaceutical Co., Ltd. Sustained release pharmaceutical composition of solid medical material
US4404183A (en) * 1979-07-05 1983-09-13 Yamanouchi Pharmaceutical Co., Ltd. Sustained release pharmaceutical composition of solid medical material
US4248857A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US5051262A (en) * 1979-12-07 1991-09-24 Elan Corp., P.L.C. Processes for the preparation of delayed action and programmed release pharmaceutical forms and medicaments obtained thereby
EP0108218A3 (en) * 1982-10-08 1984-11-28 Verex Laboratories, Inc. Constant release rate solid oral dosage formulation of pharmaceutical compounds having a high degree of water solubility
US4720387A (en) * 1983-06-22 1988-01-19 Shionogi & Co., Ltd. Sustained-release preparation of pinacidil
AT391078B (en) * 1983-11-11 1990-08-10 Egyt Gyogyszervegyeszeti Gyar METHOD FOR THE PRODUCTION OF GRANULES OR OF PRESS TABLETS WITH REGULATED DELIVERY OF ACTIVE SUBSTANCES
US4647599A (en) * 1983-11-11 1987-03-03 Egyt Gyogyszervegyeszeti Cyar Sustained release pharmaceutical tablets and process for the preparation thereof
WO1986000802A1 (en) * 1984-07-23 1986-02-13 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4744976A (en) * 1984-07-23 1988-05-17 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
JPS61502759A (en) * 1984-07-23 1986-11-27 ゼタクロン，インコ−ポレイテツド Erodible matrix for use in pre-release biologically active compositions
US4774074A (en) * 1984-07-23 1988-09-27 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4806337A (en) * 1984-07-23 1989-02-21 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4708874A (en) * 1985-03-13 1987-11-24 Rijksuniversiteit Groningen Devices for the controlled release of active substances, as well as process for the preparation thereof
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US4839177A (en) * 1985-12-20 1989-06-13 Jagotec Ag System for the controlled-rate release of active substances
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4798725A (en) * 1986-06-16 1989-01-17 Norwich Eaton Pharmaceuticals, Inc. Sustained release capsule
US4772473A (en) * 1986-06-16 1988-09-20 Norwich Eaton Pharmaceuticals, Inc. Nitrofurantoin dosage form
EP0309404A3 (en) * 1987-09-25 1990-03-14 Battelle Memorial Institute Bioadhesive copolymer useful as a carrier in the administration of medicines by direct contact
US5618560A (en) * 1988-03-24 1997-04-08 Bm Research A/S Controlled release erodible composition
US5213808A (en) * 1989-09-22 1993-05-25 Buhk Meditec A/A Controlled release article with pulsatile release
US5302398A (en) * 1991-04-12 1994-04-12 Alfa Wassermann S.P.A. Gastroresistant pharmaceutical formulations for oral administration containing salts of bile acids
US20040185098A1 (en) * 1991-11-27 2004-09-23 Benjamin Oshlack Controlled release oxycodone compositions
US20060057210A1 (en) * 1991-11-27 2006-03-16 Purdue Pharma L.P. Controlled release oxycodone compositions
US20040096500A1 (en) * 1991-11-27 2004-05-20 Benjamin Oshlack Controlled release oxycodone compositions
US6294195B1 (en) 1991-12-24 2001-09-25 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US20040121001A1 (en) * 1991-12-24 2004-06-24 Benjamin Oshlack Orally adminstrable opioid formulations having extended duration of effect
US20090068269A1 (en) * 1991-12-24 2009-03-12 Purdue Pharma L.P. Orally adminstrable opioid formulations having extended duration of effect
US7270831B2 (en) 1991-12-24 2007-09-18 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US20080181941A1 (en) * 1991-12-24 2008-07-31 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US20030180361A1 (en) * 1991-12-24 2003-09-25 Benjamin Oshlack Orally administrable opioid formulations having extended duration of effect
US6572885B2 (en) 1991-12-24 2003-06-03 Euro-Celtique, S.A. Orally administrable opioid formulations having extended duration of effect
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US20100092570A1 (en) * 1992-11-25 2010-04-15 Purdue Pharma L.P. Controlled release oxycodone compositions
US20060099263A1 (en) * 1993-05-27 2006-05-11 Edgren David E Antidepressant dosage form
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US20100034876A1 (en) * 1993-06-18 2010-02-11 Purdue Pharma L.P. Controlled release oxycodone compositions
US6143322A (en) * 1993-07-01 2000-11-07 Purdue Pharma L.P. Method of treating humans with opioid formulations having extended controlled release
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US6103261A (en) * 1993-07-01 2000-08-15 Purdue Pharma Lp Opioid formulations having extended controlled release
US6143328A (en) * 1993-07-27 2000-11-07 Euro-Celtique, S.A. Sustained release compositions and a method of preparing pharmaceutical compositions
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
GB2281204A (en) * 1993-07-27 1995-03-01 Euro Celtique Sa Sustained release morphine compositions
US20070232667A1 (en) * 1993-09-20 2007-10-04 Eugenio Cefali Methods for Treating Hyperlipidemia With Intermediate Release Nicotinic Acid Compositions Having Unique Biopharmaceutical Characteristics
US20070237819A1 (en) * 1993-09-20 2007-10-11 Bova David J Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US20070224270A1 (en) * 1993-09-20 2007-09-27 Bova David J Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor
US20070225341A1 (en) * 1993-09-20 2007-09-27 Bova David J Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US7998506B2 (en) 1993-09-20 2011-08-16 Kos Life Sciences, Inc. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US20070225342A1 (en) * 1993-09-20 2007-09-27 Bova David J Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) * 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US20080045573A1 (en) * 1993-09-20 2008-02-21 Bova David J Methods and Sustained Release Nicotinic Acid Compositions for Treating Hyperlipidemia
US20050118257A1 (en) * 1993-09-20 2005-06-02 Bova David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
GB2284760A (en) * 1993-11-23 1995-06-21 Euro Celtique Sa Sustained release morphine compositions
US20080031963A1 (en) * 1993-11-23 2008-02-07 Purdue Pharma L.P. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
GB2284760B (en) * 1993-11-23 1998-06-24 Euro Celtique Sa A method of preparing pharmaceutical compositions by melt pelletisation
US20100209514A1 (en) * 1993-11-23 2010-08-19 Sackler Richard S Method of treating pain by administering 24 hour oral oploid formulations exhibiting rapid rate of initial rise of plasma drug level
US20070237832A1 (en) * 1993-11-23 2007-10-11 Purdue Pharma L.P. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US20070237833A1 (en) * 1993-11-23 2007-10-11 Purdue Pharma L.P. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US20060269604A1 (en) * 1993-11-23 2006-11-30 Purdue Pharma L.P. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5672360A (en) * 1993-11-23 1997-09-30 Purdue Pharma, L.P. Method of treating pain by administering 24 hour oral opioid formulations
US6306439B1 (en) 1994-02-28 2001-10-23 Bayer Aktiengesellschaft Expandable pharmaceutical forms
US5651985A (en) * 1994-02-28 1997-07-29 Bayer Aktiengesellschaft Expandable pharmaceutical forms
US8629179B2 (en) 1996-11-12 2014-01-14 Alza Corporation Methods and devices for providing prolonged drug therapy
US20050238709A1 (en) * 1996-11-12 2005-10-27 Alza Corporation Methods and devices for providing prolonged drug therapy
US9029416B2 (en) 1996-11-12 2015-05-12 Alza Corporation Methods and devices for providing prolonged drug therapy
US20100093796A1 (en) * 1996-11-12 2010-04-15 Gupta Suneel K Methods and devices for providing prolonged drug therapy
US20050025832A1 (en) * 1996-11-12 2005-02-03 Alza Corporation Methods and devices for providing prolonged drug therapy
US9144549B2 (en) 1996-11-12 2015-09-29 Alza Corporation Methods and devices for providing prolonged drug therapy
US20050025831A1 (en) * 1996-11-12 2005-02-03 Alza Corporation Methods and devices for providing prolonged drug therapy
US9000038B2 (en) 1996-11-12 2015-04-07 Alza Corporation Methods and devices for providing prolonged drug therapy
US8163798B2 (en) 1996-11-12 2012-04-24 Alza Corporation Methods and devices for providing prolonged drug therapy
US8936810B2 (en) 1998-06-03 2015-01-20 Alza Corporation Methods and apparatus for determining formulation orientation of multi-layered pharmaceutical dosage forms
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
JP2008201805A (en) * 1999-10-27 2008-09-04 Anesta Corp Oral transmucosal drug dosage using solid solution
EP1242013A4 (en) * 1999-10-27 2005-06-15 Anesta Corp Oral transmucosal drug dosage using solid solution
JP2003512402A (en) * 1999-10-27 2003-04-02 アネスタ・コーポレーション Oral transmucosal drug dosage form using solid solution
US9320717B2 (en) 1999-10-29 2016-04-26 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8975273B2 (en) 1999-10-29 2015-03-10 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8980291B2 (en) 1999-10-29 2015-03-17 Purdue Pharma L.P. Controlled release hydrocodone formulations
US20040266807A1 (en) * 1999-10-29 2004-12-30 Euro-Celtique, S.A. Controlled release hydrocodone formulations
US9669024B2 (en) 1999-10-29 2017-06-06 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9669022B2 (en) 1999-10-29 2017-06-06 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9278074B2 (en) 1999-10-29 2016-03-08 Purdue Pharma L.P. Controlled release hydrocodone formulations
US7943174B2 (en) 1999-10-29 2011-05-17 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9675611B1 (en) 1999-10-29 2017-06-13 Purdue Pharma L.P. Methods of providing analgesia
US10076516B2 (en) 1999-10-29 2018-09-18 Purdue Pharma L.P. Methods of manufacturing oral dosage forms
US9056107B1 (en) 1999-10-29 2015-06-16 Purdue Pharma L.P. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US20110052689A1 (en) * 2000-04-28 2011-03-03 Reckitt Benckiser Inc. Sustained release of guaifenesin
US7985420B2 (en) 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US20040018233A1 (en) * 2000-04-28 2004-01-29 Davis Robert D. Sustained release of guaifenesin
US20030215508A1 (en) * 2000-04-28 2003-11-20 Davis Robert D. Sustained release of guaifenesin combination drugs
US20050276852A1 (en) * 2000-04-28 2005-12-15 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US20040022851A1 (en) * 2000-04-28 2004-02-05 Davis Robert D. Sustained release of guaifenesin combination drugs
US8012504B2 (en) 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7985421B2 (en) 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US9669023B2 (en) 2000-10-30 2017-06-06 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9572805B2 (en) 2000-10-30 2017-02-21 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9682077B2 (en) 2000-10-30 2017-06-20 Purdue Pharma L.P. Methods of providing analgesia
US10022368B2 (en) 2000-10-30 2018-07-17 Purdue Pharma L.P. Methods of manufacturing oral formulations
US8142811B2 (en) 2000-10-30 2012-03-27 Purdue Pharma L.P. Controlled release hydrocodone formulations
US20040047907A1 (en) * 2000-10-30 2004-03-11 Benjamin Oshlack Controlled release hydrocodone formulations
US8231898B2 (en) 2000-10-30 2012-07-31 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9289391B2 (en) 2000-10-30 2016-03-22 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8361499B2 (en) 2000-10-30 2013-01-29 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8551520B2 (en) 2000-10-30 2013-10-08 Purdue Pharma L.P. Controlled release hydrocodone
US9504681B2 (en) 2000-10-30 2016-11-29 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8647667B2 (en) 2000-10-30 2014-02-11 Purdue Pharma, L.P. Controlled release hydrocodone formulations
US8715721B2 (en) 2000-10-30 2014-05-06 Purdue Pharma L.P. Controlled release hydrocodone
US9572804B2 (en) 2000-10-30 2017-02-21 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8951555B1 (en) 2000-10-30 2015-02-10 Purdue Pharma L.P. Controlled release hydrocodone formulations
US7514100B2 (en) 2000-10-30 2009-04-07 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9526724B2 (en) 2000-10-30 2016-12-27 Purdue Pharma L.P. Controlled release hydrocodone formulations
US6733783B2 (en) 2000-10-30 2004-05-11 Euro-Celtique S.A. Controlled release hydrocodone formulations
US9023401B1 (en) 2000-10-30 2015-05-05 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9205055B2 (en) 2000-10-30 2015-12-08 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9517236B2 (en) 2000-10-30 2016-12-13 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9056052B1 (en) 2000-10-30 2015-06-16 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9060940B2 (en) 2000-10-30 2015-06-23 Purdue Pharma L.P. Controlled release hydrocodone
US9205056B2 (en) 2000-10-30 2015-12-08 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9198863B2 (en) 2000-10-30 2015-12-01 Purdue Pharma L.P. Controlled release hydrocodone formulations
US20040170680A1 (en) * 2001-05-02 2004-09-02 Benjamin Oshlack Once-a-day oxycodone formulations
US7135436B2 (en) 2003-05-05 2006-11-14 J.F. Daley International, Ltd. Solid algicide, preparation and usage in recirculating water
US20040222166A1 (en) * 2003-05-05 2004-11-11 J.F. Daley International, Ltd. Solid algicide, preparation and usage in recirculating water
US20060263427A1 (en) * 2005-05-03 2006-11-23 Roberts Richard H Quinine formulations
US20090239902A1 (en) * 2005-05-03 2009-09-24 Jie Du Quinine dosage forms and methods of use thereof
US20070196491A1 (en) * 2006-01-27 2007-08-23 Eurand, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
US20070190145A1 (en) * 2006-01-27 2007-08-16 Eurand, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
US20080075770A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophilic abuse deterrent delivery system
US20080075771A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophilic opioid abuse deterrent delivery system using opioid antagonists
US20080075768A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophobic opioid abuse deterrent delivery system using opioid antagonists
US20080020032A1 (en) * 2006-07-21 2008-01-24 Michael Crowley Hydrophobic abuse deterrent delivery system for hydromorphone
US20080055036A1 (en) * 2006-08-29 2008-03-06 International Business Machines Corporation Electrical component tuned by conductive layer deletion
US9622966B2 (en) * 2007-07-06 2017-04-18 Basf Corporation Gastroretentive composition on the basis of a water-soluble reaction product from a vinyl group-containing precursor
US20120269866A1 (en) * 2007-07-06 2012-10-25 Shaukat Ali Gastroretentive Composition On The Basis Of A Water-Soluble Reaction Product From A Vinyl Group-Containing Precursor
US20090232885A1 (en) * 2008-03-12 2009-09-17 Gopi Venkatesh Drug Delivery Systems Comprising Weakly Basic Drugs and Organic Acids
US8133506B2 (en) 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
US20110150992A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and method of use thereof
US12370189B2 (en) 2014-10-21 2025-07-29 Rb Health (Us) Llc Pharmaceutical formulation
WO2016123482A3 (en) * 2015-01-30 2016-10-06 Mylan, Inc. Sustained-release oral dosage forms for low aqueous solubility compounds
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
US12257218B2 (en) 2015-10-09 2025-03-25 Rb Health (Us) Llc Pharmaceutical formulation

Similar Documents

Publication Publication Date Title
US3634584A (en) Sustained action dosage form
US3074852A (en) Pharmaceuticals with delayed release
CA1295247C (en) Sustained release capsule
EP0235986B2 (en) Slow release formulation
US4083949A (en) New oral form of medicament and a method for producing it
US6238697B1 (en) Methods and formulations for making bupropion hydrochloride tablets using direct compression
US4832957A (en) Controlled release combination of carbidopa/levodopa
US5811126A (en) Controlled release matrix for pharmaceuticals
AU712464B2 (en) Improvements in or relating to organic compositions
US4900755A (en) Controlled release combination of carbidopa/levodopa
JP2509226B2 (en) Nitrofurantoin dosage form
US4983400A (en) Controlled release combination of carbidopa/levodopa
JPH0688905B2 (en) Solid pharmaceutical preparation for oral administration containing erythromycin derivative and method for producing the same
US3453360A (en) Universally useful stock material for manufacturing plastic dosage units by compression tableting processes
JPH07165615A (en) Long-acting heterodisperse hydrogel system for insoluble drugs
JPH10511407A (en) Sustained release matrix for high dose poorly soluble drugs
EA004443B1 (en) Pharmaceutical formulation for controlled release of ciprofloxacin for one administration per day
RU2001110355A (en) NON-INFLUENCE OF FOOD PHARMACEUTICAL DOSED DRUG FORMS OF LONG-TERM ACTION CONTAINING MANY UNITS, AND METHOD FOR PRODUCING THEM
HU190619B (en) Process for producing tablets with controlled dissolution of active ingredients
WO1992004013A1 (en) Multiparticulate sustained release matrix system
JP2686215B2 (en) Sustained-release tablets
IL32200A (en) Sustained release drug composition
US6726930B1 (en) Sustained release heterodisperse hydrogel systems for insoluble drugs
KR20040047920A (en) Solid pharmaceutical formulation for a piperazine urea derivative
JP2006525356A (en) Tablets and methods for sustained release of hydrophilic and other active substances